0.140
0.00 (2.19%)
| Previous Close | 0.137 |
| Open | 0.140 |
| Volume | 225,751 |
| Avg. Volume (3M) | 324,772 |
| Market Cap | 39,874,980 |
| Price / Sales | 1.31 |
| Price / Book | 2.33 |
| 52 Weeks Range | |
| Earnings Date | 25 Aug 2025 - 29 Aug 2025 |
| Profit Margin | -32.78% |
| Operating Margin (TTM) | -41.67% |
| Diluted EPS (TTM) | -0.040 |
| Quarterly Revenue Growth (YOY) | 27.50% |
| Total Debt/Equity (MRQ) | 19.43% |
| Current Ratio (MRQ) | 1.84 |
| Operating Cash Flow (TTM) | -7.26 M |
| Levered Free Cash Flow (TTM) | -4.73 M |
| Return on Assets (TTM) | -21.93% |
| Return on Equity (TTM) | -49.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (AU) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | NOVA EYE FPO [EYE] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.25 |
|
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 15.14% |
| % Held by Institutions | 18.28% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |